Hemostemix Announces Strategic Manufacturing Partnership with CytoImmune Therapeutics and $1,800,000 in Financing Commitments

Stock Information for Hemostemix

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Hemostemix

Hemostemix Closes its Funded Manufacturing Services Agreement with CytoImmune, Restarting Production of ACP-01
Hemostemix Announces Trademark Granted by Switzerland and Interest Payment
Hemostemix Announces Engagement of Oak Hill Asset Management Inc.
Hemostemix Announces Updated Phase II Randomized Clinical Trial Results Published by the Journal of Biomedical Research and Environmental Sciences
Hemostemix Clarifies its October 3, 2023 News Release
Hemostemix's 4th Heart Study Published in Stem Cell Research & Therapy Confirms Breakthrough Treatment for Heart Disease
Hemostemix Announces Amendment of its $2.5 Million 5 Year Convertible Debenture Issued on June 11, 2021, Resulting in an Expected Interest Saving of Approximately $570,000
Hemostemix Closed $320,125 Private Placement

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.